Raymond De Vré Biography and Net Worth

Director of Codexis

Raymond De Vré brings over 20 years of executive-level experience to Codexis. He founded and currently serves as CEO and Managing Director at RADV Advisory, an independent strategic and operational advisory company focused on investments in the global healthcare and contract development and manufacturing organization (CDMO) sector. He joined RADV from PolyPeptide Group, a CDMO focused on peptide- and oligonucleotide-based therapies for pharmaceutical and biotech companies globally, where he served as CEO until April 2023. Prior to PolyPeptide, Dr. De Vré held multiple senior leadership roles at Dr. Reddy’s Laboratories from 2012 to 2021, including Senior Vice President, Global Business Operations and Strategy, Biologics and Vice President, Commercial Biologics. Earlier in his career, he held roles of increasing responsibility at McKinsey & Company, ultimately ascending to the role of Partner. Dr. De Vré holds a PhD in Applied Physics from Stanford University and a master’s degree in engineering from Université Libre de Bruxelles.

What is Raymond De Vré's net worth?: The estimated net worth of Raymond De Vré is at least $187.43 thousand as of June 11th, 2026. Dr. De Vré owns 84,811 shares of Codexis stock worth more than $187,432 as of July 20th. This net worth estimate does not reflect any other investments that Dr. De Vré may own. Learn More about Raymond De Vré's net worth.
How do I contact Raymond De Vré?: The corporate mailing address for Dr. De Vré and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Raymond De Vré's contact information.
Has Raymond De Vré been buying or selling shares of Codexis?: Raymond De Vré has not been actively trading shares of Codexis during the last quarter. Most recently, Vre Raymond De sold 2,605 shares of the business's stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $2.37, for a transaction totalling $6,173.85. Following the completion of the sale, the director now directly owns 84,811 shares of the company's stock, valued at $201,002.07. Learn More on Raymond De Vré's trading history.
Who are Codexis' active insiders?: Codexis' insider roster includes Raymond De Vré (Director), Byron Dorgan (Director), Georgia Erbez (Chief Financial Officer and Chief Business Officer), Bernard Kelley (Director), Stefan Lutz (Chief Scientific Officer), Alison Moore (President and CEO), John Nicols (CEO), Kevin Norrett (COO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.
Are insiders buying or selling shares of Codexis?: In the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 35,774 shares worth more than $65,308.44. The most recent insider tranaction occured on June, 11th when Director Vre Raymond De sold 2,605 shares worth more than $6,173.85. Insiders at Codexis own 3.5% of the company. Learn More about insider trades at Codexis.
Information on this page was last updated on 6/11/2026.

Raymond De Vré Insider Trading History at Codexis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/11/2026	Sell	2,605	$2.37	$6,173.85	84,811

Raymond De Vré Buying and Selling Activity at Codexis

Codexis Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Today's Range

Now: $2.21

$2.14

$2.27

50 Day Range

MA: $2.48

$2.13

$2.80

2 Week Range

Now: $2.21

$0.96

$3.87

Volume

506,418 shs

Average Volume

812,612 shs

Market Capitalization

$200.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.5